| 1.69 0.03 (1.81%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.22 | 1-year : | 2.83 |
| Resists | First : | 1.9 | Second : | 2.43 |
| Pivot price | 1.82  |
|||
| Supports | First : | 1.05 | Second : | 0.88 |
| MAs | MA(5) : | 1.59 |
MA(20) : | 1.8 |
| MA(100) : | 1.84 |
MA(250) : | 5.79 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 22.6 |
D(3) : | 16.7 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 13.42 | Low : | 0.61 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BFRI ] has closed above bottom band by 37.2%. Bollinger Bands are 2.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.69 - 1.7 | 1.7 - 1.71 |
| Low: | 1.59 - 1.6 | 1.6 - 1.6 |
| Close: | 1.68 - 1.69 | 1.69 - 1.7 |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Tue, 19 Mar 2024
Biofrontera Inc. (NASDAQ:BFRI) Q4 2023 Earnings Call Transcript - Yahoo Finance
Mon, 18 Mar 2024
Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript - Seeking Alpha
Fri, 15 Mar 2024
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update - Yahoo Finance
Fri, 08 Mar 2024
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024 - Yahoo Finance
Tue, 20 Feb 2024
Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules - Yahoo Finance
Tue, 06 Feb 2024
Biofrontera FDA Review Advances Ameluz® Dosage Expansion - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 5 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 28.1 (%) |
| Held by Institutions | 39.1 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 110 (K) |
| EPS | -13.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.16 |
| Profit Margin | -59.1 % |
| Operating Margin | -36.5 % |
| Return on Assets (ttm) | -33.9 % |
| Return on Equity (ttm) | -140.5 % |
| Qtrly Rev. Growth | 4.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 6.69 |
| EBITDA (p.s.) | -4.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.53 |
| Price to Sales | 0.25 |
| Price to Cash Flow | -0.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|